Huisheng Biological: In the first half of this year, we have obtained seven approvals for pet products, greatly expanding our pet product line.

Huisheng Biology stated on the investor interaction platform that the pet medicine sector is one of the company's key development directions. The company has adjusted resource allocation, increased investment in pet medicine research and development, and market channel construction. It now has an independent and specialized pet medicine research and development team, and has already obtained approval for 7 pet products in the first half of this year, greatly expanding its pet product line. The company's pet medicine products mainly involve categories such as deworming, antipyretic and analgesic, skin medications, internal medicine diseases, and functional health products in the pet sector.